Orserdu (Elacestrant HCl) Patent Expiration, LOE Window & CMS Spending
Orserdu (Elacestrant HCl) by Stemline Therapeutics: FDA Orange Book core substance LOE 2038-01-05, 0 AB generics, $293.5M 2024 CMS Part D & Medicaid spend, and $7,123 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Stemline Therapeutics |
| FDA Application & Pathway | N217639 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-01-05 |
| Last Listed Patent or Exclusivity Date | 2038-01-05 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $293.5M |
| 2024 Medicare Part D Spend | $258.8M |
| 2024 Medicaid Spend | $34.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($7,123 intro WAC) |